Pfizer’s Target Boosted at MKM Partners; Valuation Looks Attractive (PFE)

By Staff,

Shutterstock photo

Pharmaceuticals maker Pfizer Inc. ( PFE ) on Monday received some bullish commentary from analysts at MKM Partners.

The firm reiterated its "Buy" rating on PFE and lifted its price target from $27 to $29. That new target suggests a 14% upside to the stock's Friday closing price of $25.52.

An MKM analyst commented, "Our price target is based on what we consider to be a fair multiple, parity with the group 2013E multiple of 12.7x applied to 2013E PFE earnings of $2.26. Our target price is based on our 3D valuation framework. Pfizer scores below average on its 2012E-2016E pipeline and has the least patent exposure and a slightly below-average score on company-specific factors."

Pfizer shares posted small losses in premarket trading Monday.

The Bottom Line
We have been recommending shares of Pfizer ( PFE ) since Mar.2, 2012, when the stock was trading at $21.49. The company has a 3.45% dividend yield, based on Friday's closing stock price of $25.52.

Pfizer Inc. ( PFE ) is a "Recommended" dividend stock, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by

This article appears in: Investing Stocks
Referenced Stocks: PFE

More from

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by